High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C

BACKGROUND: High prices of direct acting antivirals (DAAs) for hepatitis C virus (HCV) can lead to restrictions on access to treatment in high- and middle-income countries. An increasing number of people in these countries are treating their HCV infection with generic drugs produced in India, China,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Andrew, Khwairakpam, Giten, Wang, James, Golovin, Sergey, Dragunova, Julia, Smith, Rachel, Houghton-Price, Vicky, Korologou-Linden, Roxanna, Nath, Sanjay, Savage, Anna, Jefferys, Greg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632545/
https://www.ncbi.nlm.nih.gov/pubmed/29057082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632545/
https://www.ncbi.nlm.nih.gov/pubmed/29057082

Ejemplares similares